Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung14: osimertinib with or without datopotamab deruxtecan in first-line EGFR-mutant advanced non-small cell lung cancer
2023-509883-89-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Osimertinib + datopotamab deruxtecan with Osimertinib (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2025; status: authorised.
02
Drugs
osimertinibdatopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509883-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509883-89-00.